BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33652355)

  • 1. Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy.
    Ma Z; Ji Y; Yu Y; Liang D
    Eur J Med Chem; 2021 Apr; 216():113247. PubMed ID: 33652355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.
    Wang C; Zhang Y; Shi L; Yang S; Chang J; Zhong Y; Li Q; Xing D
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1437-1453. PubMed ID: 35589670
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
    J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
    Ohoka N
    Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER).
    Ohoka N; Ujikawa O; Shimokawa K; Sameshima T; Shibata N; Hattori T; Nara H; Cho N; Naito M
    Chem Pharm Bull (Tokyo); 2019 Mar; 67(3):203-209. PubMed ID: 30369550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of SNIPERs against BCR-ABL with kinase inhibitors and a method to evaluate their growth inhibitory activity derived from BCR-ABL degradation.
    Cho N; Naito M
    Methods Enzymol; 2023; 681():41-60. PubMed ID: 36764763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted protein degradation and drug discovery.
    Naito M
    J Biochem; 2022 Jul; 172(2):61-69. PubMed ID: 35468190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands.
    Shibata N; Nagai K; Morita Y; Ujikawa O; Ohoka N; Hattori T; Koyama R; Sano O; Imaeda Y; Nara H; Cho N; Naito M
    J Med Chem; 2018 Jan; 61(2):543-575. PubMed ID: 28594553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.
    Shibata N; Miyamoto N; Nagai K; Shimokawa K; Sameshima T; Ohoka N; Hattori T; Imaeda Y; Nara H; Cho N; Naito M
    Cancer Sci; 2017 Aug; 108(8):1657-1666. PubMed ID: 28556300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.
    Ohoka N; Morita Y; Nagai K; Shimokawa K; Ujikawa O; Fujimori I; Ito M; Hayase Y; Okuhira K; Shibata N; Hattori T; Sameshima T; Sano O; Koyama R; Imaeda Y; Nara H; Cho N; Naito M
    J Biol Chem; 2018 May; 293(18):6776-6790. PubMed ID: 29545311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNIPERs-Hijacking IAP activity to induce protein degradation.
    Naito M; Ohoka N; Shibata N
    Drug Discov Today Technol; 2019 Apr; 31():35-42. PubMed ID: 31200857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a peptide-based inducer of protein degradation targeting NOTCH1.
    Ohoka N; Misawa T; Kurihara M; Demizu Y; Naito M
    Bioorg Med Chem Lett; 2017 Nov; 27(22):4985-4988. PubMed ID: 29050782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs.
    Ishikawa M; Tomoshige S; Demizu Y; Naito M
    Pharmaceuticals (Basel); 2020 Apr; 13(4):. PubMed ID: 32326273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocols for Synthesis of SNIPERs and the Methods to Evaluate the Anticancer Effects.
    Tsukumo Y; Tsuji G; Yokoo H; Shibata N; Ohoka N; Demizu Y; Naito M
    Methods Mol Biol; 2021; 2365():331-347. PubMed ID: 34432253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs.
    Naito M; Ohoka N; Shibata N; Tsukumo Y
    Front Chem; 2019; 7():849. PubMed ID: 31921772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy.
    Ohoka N; Shibata N; Hattori T; Naito M
    Curr Cancer Drug Targets; 2016; 16(2):136-46. PubMed ID: 26560118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of nuclear receptor-degradation inducers.
    Itoh Y; Kitaguchi R; Ishikawa M; Naito M; Hashimoto Y
    Bioorg Med Chem; 2011 Nov; 19(22):6768-78. PubMed ID: 22014751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand.
    Demizu Y; Shibata N; Hattori T; Ohoka N; Motoi H; Misawa T; Shoda T; Naito M; Kurihara M
    Bioorg Med Chem Lett; 2016 Oct; 26(20):4865-4869. PubMed ID: 27666635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein.
    Shibata N; Ohoka N; Hattori T; Naito M
    Chem Pharm Bull (Tokyo); 2019; 67(3):165-172. PubMed ID: 30827996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of IAP-recruiting BCL-X
    Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.